<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02374099</url>
  </required_header>
  <id_info>
    <org_study_id>CC-486-BRSTM-001</org_study_id>
    <nct_id>NCT02374099</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant</brief_title>
  <official_title>A Phase 2, Randomized, Open-label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women With ER+, HER2- Metastatic Breast Cancer Who Have Progressed on an Aromatase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to Assess the Efficacy and Safety of the Epigenetic Modifying
      Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women
      with ER+, HER2- Metastatic Breast Cancer Who Have Progressed on an Aromatase Inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, two-arm study assessing the efficacy and safety of the
      combination of fulvestrant with CC-486 in subjects with ER+, HER2- metastatic breast cancer
      who have progressed after prior AI.

      Approximately 92 subjects will be enrolled and assigned randomly in a 1:1 ratio to one of two
      treatment arms:

        -  Arm A: CC-486 300 mg and fulvestrant 500 mg: 46 subjects

        -  Arm B: Fulvestrant 500 mg: 46 subjects Each cycle will be 28 days. CC-486 will be
           administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle.
           Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on
           days 1 and 15 of cycle 1 and day 1 of subsequent cycles.

      Safety will be evaluated by an independent data monitoring committee (DMC) after a total of
      approximately 32 subjects have completed at least 1 treatment cycle.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 13, 2015</start_date>
  <completion_date type="Anticipated">December 15, 2017</completion_date>
  <primary_completion_date type="Actual">December 13, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time period of progression free survival of patients in the combination arm versus the Fulvestrant only arm.</measure>
    <time_frame>approximately 21 months</time_frame>
    <description>Estimation of the hazard ratio of PFS of the combination arm relative to fulvestrant monotherapy arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Approximately 28 months</time_frame>
    <description>The combined incidence of CR and PR, confirmed no less than 4 weeks after the criteria for response are first met, based on RECIST Version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Benefit Rate</measure>
    <time_frame>Approximately 28 months</time_frame>
    <description>Complete response (CR) + PR + SD ( ≥ 24 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 28 months</time_frame>
    <description>Overall Survival (OS): time from date of randomization to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Duration</measure>
    <time_frame>Approximately 28 months</time_frame>
    <description>Duration of response in subjects with a confirmed objective CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Approximately 28 months</time_frame>
    <description>incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 and higher AEs, AEs of special interest, and laboratory abnormalities and other safety parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>CC-486 and fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-486 300mg by mouth (PO) daily on days 1-21 of each 28 day cycle and Fulvestrant 500mg by intramuscular (IM) injection on Days 1 and 15 of cycle 1 and day 1 of each subsequent cycle every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-486</intervention_name>
    <description>Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle</description>
    <arm_group_label>CC-486 and fulvestrant</arm_group_label>
    <other_name>Oral Azacitidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.</description>
    <arm_group_label>CC-486 and fulvestrant</arm_group_label>
    <arm_group_label>Fulvestrant</arm_group_label>
    <other_name>foslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is female ≥ 18 years of age (at the time of signing the informed consent form)
             with metastatic breast cancer not amenable to curative treatment by surgery or
             radiotherapy.

          -  Subject is considered postmenopausal

          -  Subject has a histologically and/or cytologically confirmed diagnosis of
             estrogen-receptor positive breast cancer by local laboratory (based on most recently
             analyzed biopsy).

          -  Subject has human epidermal growth factor receptor 2 negative (HER2-) breast cancer
             (based on most recently analyzed biopsy) defined as a negative in situ hybridization
             test or an Immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative
             in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory
             testing.

          -  Subject had disease refractory to an AI

          -  Subject has an Eastern Cooperative Oncology Group ( ECOG) performance status of 0-1.

          -  Subject has radiological documented measurable disease (ie, at least one measureable
             lesion as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1).

               -  If no measurable disease is present, then at least one predominantly lytic bone
                  lesion must be present

          -  Subject has adequate organ function.

          -  Subject has adequate bone marrow function.

        Exclusion Criteria:

          -  Subject has received &gt; 1 prior line of chemotherapy in the metastatic setting

          -  Subject has received any chemotherapy within 21 days prior to randomization.

          -  Subject has received prior treatment with fulvestrant.

          -  Subject has been previously treated with azacitidine (any formulation), decitabine, or
             any other hypomethylating agent.

          -  Subject has a history of, or current symptomatic brain metastasis.

          -  Subject has severe renal impairment (creatinine clearance &lt; 30 ml/min).

          -  Subject has an impaired ability to swallow oral medication.

          -  Subject has a contraindication to receiving IM injections (eg, bleeding disorders,
             anticoagulant use).

          -  Subject has significant active cardiac disease within the previous 6 months including
             unstable angina or angina requiring surgical or medical intervention, significant
             cardiac arrhythmia, or New York Heart Association (NYHA) class 3 or 4 congestive heart
             failure.

          -  Subject is a female of Childbearing Potential [defined as a sexually mature woman who
             (1) has not undergone hysterectomy (the surgical removal of the uterus) or bilateral
             oopherectomy (the surgical removal of both ovaries) or (2) has not been naturally
             postmenopausal for at least 12 consecutive months (ie, has had menses at any time
             during the preceding 12 consecutive months)].
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abderahim (Rahim) Fandi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ironwood Cancer and Research Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia G Piper Cancer Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Elisabeth - Service d'Oncologie</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de lutte contre le cancer Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Borddeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau Centre de Lutte Contre Le Cancer Nantes Atlantique</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg-Eppendorf / IVDP</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamatologisch Onkologische Praxis Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TU München - Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele S.r.l.</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IEO- Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Citta della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino, Piemonte</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Universitario La Coruna</name>
      <address>
        <city>La Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de La Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <disposition_first_submitted>November 14, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>November 14, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 17, 2017</disposition_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Her2 -</keyword>
  <keyword>ER+</keyword>
  <keyword>CC-486 (ORAL AZACITIDINE)</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Oralazacitidine</keyword>
  <keyword>Fulvestrant</keyword>
  <keyword>Epigenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

